SCHEMBL121422

SCHEMBL121422

Cc1c(C(=O)O)cccc1-c1ccccc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HNF4A P41235 1/20 0.63
MYC P01106 1/20 0.56
PDCD1 Q15116 1/20 0.53
CD274 Q9NZQ7 1/20 0.53
FABP4 P15090 2/20 0.53
FABP3 P05413 1/20 0.53
FABP5 Q01469 1/20 0.53
PTGER1 P34995 1/20 0.53
BCAT2 O15382 1/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
MEN1 O00255 2/20 0.52
KMT2A Q03164 2/20 0.52
ALDH1A1 P00352 5/20 0.51
L3MBTL1 Q9Y468 3/20 0.51
HPGD P15428 2/20 0.51
POLB P06746 1/20 0.51
NPC1 O15118 1/20 0.51
RAB9A P51151 1/20 0.51
ALOX15 P16050 1/20 0.50
TSHR P16473 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28429025 0.93 HNF4A (0.56) HNF4AMYCPDCD1CD274FABP4
SCHEMBL27499893 0.92 HNF4A (0.59) HNF4AMYCPDCD1CD274FABP4
SCHEMBL5046158 0.87 MYC (0.59) HNF4AMYCPTGER1SMN1; SMN2MEN1
SCHEMBL6440453 0.87 HSD17B10 (0.53) HNF4AMYCFABP4FABP3FABP5
Phthalic Acid SCHEMBL29032500 0.87 MYC (0.61) HNF4AMYCPDCD1CD274FABP4
SCHEMBL13065950 0.86 PDCD1 (0.52) HNF4AMYCPDCD1CD274FABP4
SCHEMBL24665235 0.85 SLC6A4 (0.53) HNF4AMYCPTGER1SMN1; SMN2ALDH1A1
SCHEMBL16247703 0.85 AKR1C2 (0.51) HNF4AMYCPTGER1SMN1; SMN2MEN1
Biphenyl SCHEMBL27319576 0.85 NPC1 (0.60) HNF4AMYCFABP4MEN1KMT2A
SCHEMBL30034930 0.85 BCAT2 (0.69) HNF4AMYCPDCD1CD274BCAT2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 172 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4661890-A1 PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS Purdue Research Foundation (US) 2025-12-17 EP claimed
WO-2024167565-A1 PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS PURDUE RESEARCH FOUNDATION (US) 2024-08-15 WO claimed
CN-108997164-A 2- methyl -3- phenylbenzohydrazide and its synthetic method 安康学院 2018-12-14 CN claimed
CN-108947866-A N-(2- methyl -3- Phenylbenzoyl)-N '-tertiary butyl hydrazine and its synthetic method 安康学院 2018-12-07 CN claimed
CN-106715557-A9 Monobenzoate analogs useful as plasticizers in plastisol compositions 艾默罗德卡拉玛化学品公司 2017-08-25 CN claimed
CN-106715557-A Monobenzoate analogs useful as plasticizers in plastisol compositions 艾默罗德卡拉玛化学品公司 2017-05-24 CN claimed
CN-101981003-B Amide compounds, compositions and uses thereof RENOVIS INC 2014-07-02 CN claimed
CN-101981003-A Amide compounds, compositions and uses thereof RENOVIS INC 2011-02-23 CN claimed
WO-2010118241-A2 INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (US) 2010-10-14 WO claimed
CN-101135683-A Bifenthrin antigen, antibody and uses thereof UNIV NANJING AGRICULTURAL (CN) 2008-03-05 CN claimed
WO-2001034197-A2 ONCOLYTIC COMBINATIONS FOR THE TREATMENT OF CANCER ELI LILLY AND COMPANY (US) 2001-05-17 WO claimed
EP-4661890-A1 PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS Purdue Research Foundation (US) 2025-12-17 EP disclosed
US-12187811-B2 Cyclic peptide compound simulating natural product structure, and method for preparation thereof NANKAI UNIVERSITY (CN) 2025-01-07 US disclosed
CN-116041277-B Phenyl and biphenyl substituted five-membered heterocyclic compound, preparation method, pharmaceutical composition and application thereof 中国药科大学 2024-11-01 CN disclosed
WO-2024167565-A1 PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS PURDUE RESEARCH FOUNDATION (US) 2024-08-15 WO disclosed
WO-2004080376-A2 HYDROXYETHYLAMINE COMPOUNDS HAVING ASP2 INHIBITORY ACTIVITY FOR THE TREATMENT OF ALZHEIMER’S DISEASE GLAXO GROUP LIMITED (GB) 2004-09-23 WO disclosed
WO-2003101928-A1 NOVEL LIGANDS THAT ARE INHIBITORS OF THE RAR RECEPTORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2003-12-11 WO disclosed
WO-2003097617-A1 CYSTEINE PROTEASE INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2003-11-27 WO disclosed
WO-2001034198-A2 ONCOLYTIC COMBINATIONS FOR THE TREATMENT OF CANCER ELI LILLY AND COMPANY (US) 2001-05-17 WO disclosed
CN-1120838-A Heterocyclic derivatives in the treatment of ischaemia and related diseases SYNTEX PHARMA LTD (GB) 1996-04-17 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12187811-B2 Cyclic peptide compound simulating natural product structure, and method for preparation thereof VIP, PTMS, NPPA HNF4A 3216/4885MYC 1029/4885PDCD1 122/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.